We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$46.3M
1-Year Est. Return
48.82%
This Fund
S&P 500
This Quarter
Est. Return
+25.68%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$746M
AUM Growth
+$200M
(+37%)
Cap. Flow
+$60.8M
Cap. Flow
% of AUM
8.15%
Top 10 Holdings %
Top 10 Hldgs %
76.52%
Holding
190
New
78
Increased
30
Reduced
20
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MON
Monsanto Co
MON
|
+$6.18M |
| 2 |
Verisk Analytics
VRSK
|
+$5.61M |
| 3 |
Air Products & Chemicals
APD
|
+$4.62M |
| 4 |
DNB
Dun & Bradstreet
DNB
|
+$4.57M |
| 5 |
Honeywell
HON
|
+$4.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FNB Corp
FNB
|
+$5.19M |
| 2 |
Dover
DOV
|
+$4.9M |
| 3 |
Associated Banc-Corp
ASB
|
+$3.9M |
| 4 |
KeyCorp
KEY
|
+$3.73M |
| 5 |
PACW
PacWest Bancorp
PACW
|
+$2.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 12.55% |
| 2 | Healthcare | 6.08% |
| 3 | Industrials | 5.43% |
| 4 | Materials | 3.1% |
| 5 | Technology | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
NCR Voyix
VYX
$1.14B
| $1.12M | 0.15% |
+44,739
| New | +$1.14M |
|
|
AZPN
77
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $1.1M | 0.15% |
+19,947
| New | +$1.1M |
|
78
American Financial Group
AFG
$11.8B
| $1.09M | 0.15% |
+10,997
| New | +$1.08M |
|
79
Primerica
PRI
$9.98B
| $1.09M | 0.15% |
+14,420
| New | +$1.13M |
|
|
RDUS
80
DELISTED
Radius Health, Inc.
RDUS
| $1.09M | 0.15% |
+24,036
| New | +$919K |
|
81
Ardelyx
ARDX
$1.22B
| $1.08M | 0.14% |
211,727
+154,827
| +272% | +$1.31M |
|
82
LPL Financial
LPLA
$28.3B
| $1.07M | 0.14% |
+25,319
| New | +$1.03M |
|
83
Simpson Manufacturing
SSD
$7.72B
| $1.07M | 0.14% |
+24,586
| New | +$1.03M |
|
|
CADE
84
DELISTED
Cadence Bank
CADE
| $1.07M | 0.14% |
+35,000
| New | +$1.05M |
|
|
SIVB
85
DELISTED
SVB Financial Group
SIVB
| $1.05M | 0.14% |
6,000
+1,000
| +20% | +$179K |
|
|
ZGNX
86
DELISTED
Zogenix, Inc.
ZGNX
| $1.04M | 0.14% |
+72,091
| New | +$906K |
|
|
BLUE
87
DELISTED
bluebird bio
BLUE
| $1.04M | 0.14% |
+761
| New | +$918K |
|
|
PTLA
88
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $1.03M | 0.14% |
+18,305
| New | +$733K |
|
|
RXDX
89
DELISTED
Ignyta, Inc.
RXDX
| $958K | 0.13% |
+92,561
| New | +$752K |
|
|
AERI
90
DELISTED
Aerie Pharmaceuticals
AERI
| $947K | 0.13% |
+18,024
| New | +$839K |
|
|
TREC
91
DELISTED
Trecora Resources
TREC
| $898K | 0.12% |
79,807
-5,576
| -7% | -$62.4K |
|
|
AAMI
92
Acadian Asset Management
AAMI
$3.08B
| $885K | 0.12% |
+59,533
| New | +$881K |
|
93
Alnylam Pharmaceuticals
ALNY
$27.5B
| $863K | 0.12% |
+10,814
| New | +$691K |
|
|
FOMX
94
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $824K | 0.11% |
177,488
+75,788
| +75% | +$338K |
|
95
SEI Investments
SEIC
$12.4B
| $778K | 0.1% |
+14,464
| New | +$745K |
|
96
Blue Bird Corp
BLBD
$2.35B
| $775K | 0.1% |
+45,569
| New | +$822K |
|
|
STML
97
DELISTED
Stemline Therapeutics, Inc.
STML
| $774K | 0.1% |
+84,106
| New | +$701K |
|
98
Syndax Pharmaceuticals
SNDX
$1.69B
| $773K | 0.1% |
+55,368
| New | +$633K |
|
|
IMGN
99
DELISTED
Immunogen Inc
IMGN
| $771K | 0.1% |
+108,435
| New | +$496K |
|
100
CNO Financial Group
CNO
$5.14B
| $713K | 0.1% |
+34,151
| New | +$705K |
|
Similar funds
MCMC
RRC
PCM
NPCM
FCM
EGI
IPHI
SM
Crestline Management's Q2 2017 Portfolio in Review
As of Q2 2017, Crestline Management held 190 positions worth $746M, up 37% from $546M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Crestline Management deployed $60.8M of net new capital in Q2 2017, opening 78 new positions and adding to 30 existing holdings. Its largest new stake was Monsanto Co: 53,000 shares worth $6.27M.
By sector, the portfolio is most concentrated in Financials at 13% of assets, up from 8% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was FNB Corp, an estimated $5.19M trimmed.
- Crestline Management's largest Q2 2017 buy was Monsanto Co: 53,000 shares worth $6.27M.
- Crestline Management added most to Honeywell in Q2 2017, an estimated $4.05M increase.
- Crestline Management's biggest Q2 2017 reduction was FNB Corp, cutting an estimated $5.19M.
- Crestline Management fully exited Dover in Q2 2017, selling an estimated $4.9M.
- Crestline Management's ten largest holdings make up 77% of its $746M portfolio in Q2 2017.
- Crestline Management opened 78 new positions and closed 61 in Q2 2017.
- Crestline Management's portfolio value rose 37% quarter-over-quarter to $746M.
Based on Crestline Management's 13F filing for Q2 2017, filed 14 Aug 2017.